You can buy or sell OMED and other stocks, options, ETFs, and crypto commission-free!
OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Read More Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA.
Redwood City, California
52 Week High
52 Week Low
Seeking AlphaMar 15
OncoMed declares one-time contractual right dividend; shares up 7% premarket
The board of OncoMed Pharmaceuticals (NASDAQ:OMED) has declared a one-time special dividend to stockholders in the form of a contractual right to receive cash payments related to Celgene's (NASDAQ:CELG) option on etigilimab.
Form 425 OncoMed Pharmaceuticals Filed by: OncoMed Pharmaceuticals Inc
Item 1.01. Entry into a Material Definitive Agreement. Contingent Value Rights Agreement On March 14, 2019, OncoMed Pharmaceuticals, Inc. ( OncoMed or the Company ) entered into a Contingent Value Rights Agreement (the CVR Agreement ) with Computershare Inc., as rights agent, pursuant to which OncoMeds common stockholders of record as of the close of business on April 5, 2019 (the Record Date ) will receive one contingent value right (each, a CVR) for each outstanding share of common stock,...
Yahoo FinanceMar 15
OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights
REDWOOD CITY, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (“OncoMed”) (OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that its board of directors declared a one-time special dividend in the form of a contractual right to receive, on a pro rata basis, cash payments from OncoMed upon the actual receipt by OncoMed or its affiliates of certain contingent cash amounts in the future following the ...
-$0.22 per share
-$0.12 per share